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Abstract: Nuclear hormone receptors regulate diverse metabolic
pathways and the orphan nuclear receptor LRH-1 (also known as
NR5A2) regulates bile acid biosynthesis. Structural studies have iden-
tiﬁed phospholipids as potential LRH-1 ligands, but their functional
relevance is unclear. Here we show that an unusual phosphatidyl-
choline species with two saturated 12 carbon fatty acid acyl side
chains (dilauroyl phosphatidylcholine (DLPC)) is an LRH-1 agonist
ligand in vitro. DLPC treatment induces bile acid biosynthetic
enzymes in mouse liver, increases bile acid levels, and lowers hepatic
triglycerides and serum glucose. DLPC treatment also decreases
hepatic steatosis and improves glucose homeostasis in two mouse
models of insulin resistance. Both the antidiabetic and lipotropic
effects are lost in liver-speciﬁc Lrh-1 knockouts. These ﬁndings iden-
tify an LRH-1 dependent phosphatidylcholine signalling pathway
that regulates bile acid metabolism and glucose homeostasis.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
With the advent of increasingly sedentary lifestyles and changing
dietary patterns, the prevalence of obesity and insulin resistance
have increased and with this non-alcoholic fatty liver disease
(NAFLD) has rapidly become the most common cause of abnor-
mal liver biochemistry in many developed countries [1,2]. It is
apparent that, whilst the majority of patients with NAFLD have
simple steatosis, a signiﬁcant number exhibit steatohepatitisJournal of Hepatology 20
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patients with steatohepatitis develop complications of end-stage
liver disease during long-term follow-up and many experience
cardiovascular morbidity [1–3]. Despite substantial clinical and
basic research in this ﬁeld, a targeted therapy for NAFLD has so
far proved elusive [2].
It is recognised that increased hepatic free fatty acid (FFA) ﬂux
on a background of obesity and insulin resistance drives progres-
sive NAFLD through direct hepatocyte lipotoxicity; oxidative
stress secondary to free radical production during fatty acid oxi-
dation; endoplasmic reticulum stress; endotoxin/TLR4 induced
Kupffer cell activation and cytokine release [4]. Consequent cellu-
lar damage triggers immune mediated hepatocellular injury, acti-
vates caspase dependent and independent necrotic and apoptotic
cell death pathways and ultimately leads to stellate cell activation
and ﬁbrogenesis [5,6]. However, in recent years, as our under-
standing of the pathogenesis of NAFLD has grown, the view that
steatosis causes progressive NAFLD has been revised. This began
with the recognition that, rather than representing an initiating
‘ﬁrst hit’, steatosis was an early adaptive response to hepatocyte
stress through which potentially lipotoxic FFAs are partitioned
into relatively inert intracellular triglyceride stores [4,7]. Now,
work suggesting that a phospholipid could be an orally active,
direct therapy for NAFLD and perhaps the broader metabolic
syndrome may offer the prospect of ‘lipo-rehabilitation’.
In their recent letter to Nature, Lee and colleagues explore a
potentially important but under-researched aspect of lipid func-
tion, the role of phospholipid species as nuclear receptor agonists
[8]. Amongst its pleiotropic functions, the orphan nuclear receptor
LRH-1 (NR5A2) inﬂuences embryonic development; cellular repli-
cation and differentiation; and metabolic processes including
reverse cholesterol transport and hepatic bile acid metabolism
[9–11]. It is accepted that modest increases in bile acids may
reduce steatosis [12] and so, founded on reports that loss of
LRH-1 decreases bile acid levels [10,11], Lee et al. pursued the
hypothesis that an LRH-1 agonist would increase bile acid synthe-
sis and thus ameliorate NAFLD. Structural studies had already
identiﬁed phospholipids as potential LRH-1 ligands, although
the functional relevance of this interaction was unknown
[13,14], and so the authors screened a number of different phos-
pholipids for effects on human LRH-1 transactivation in vitro. This
led to the identiﬁcation of two phosphatidylcholine species that,
at relatively high concentrations, could activate LRH-1. Focusing
on one, dilauroyl phosphatidylcholine (DLPC), which is structurally12 vol. 56 j 987–989
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Fig. 1. The ‘Virtuous Cycle’ of insulin sensitizing effects and reduced NAFLD
induced by DLPC.
International Hepatologycharacterized by two saturated 12-carbon fatty acid acyl side
chains (C12:0/C12:0), Lee et al. ﬁrst show that oral administration
strongly induced Cyp7a1 and Cyp8b1 expression coupled with
reduced serum glucose and increased serum bile acid levels in
normal mice.
Following these encouraging data, the authors next examined
the effect of orally administered DLPC on genetically obese, insu-
lin-resistant db/db mice and in mice rendered obese and diabetic
following prolonged consumption of high fat diet. The results of
these studies were striking. DLPC induced signiﬁcant reductions
in hepatic lipid content, severity of histological NAFLD and insu-
lin resistance/glucose intolerance. Importantly, in contrast to
studies that have controlled steatosis by inhibiting triglyceride
biosynthesis through targeting expression of diacylglycerol acyl-
transferase 2 (DGAT2) [7], no signiﬁcant rise in biochemical
markers of cellular injury (ALT and AST) was observed [8].
It appears that DLPC acts in an LRH-1 dependent manner to
signiﬁcantly suppress expression of the transcription factor
SREBP-1c and its downstream target genes ACC-2, SCD-1 and FASN.
Interestingly, little or no direct effect of DLPC on expression of
genes involved in fatty acid oxidation or glucose homeostasis
was observed and DLPC did not appear to affect the nuclear recep-
tors PPARa or PPARc [8]. The authors postulate that a reduction in
hepatic de novo lipogenesis due to suppression of SREBP-1c, likely
combinedwith an increase inmitochondrial fatty acid b-oxidation
(reduced synthesis of malonyl-CoA by ACC-2 will reduce inhibi-
tion of the rate limiting enzyme controlling mitochondrial fatty
acid uptake, CPT-1a) and improved insulin sensitivity, produce a
virtuous cycle ameliorating NAFLD and the metabolic syndrome
(Fig. 1) [8]. Previous studies have also shown that LRH-1 nega-
tively regulates the hepatic acute phase response and so agonists
may offer additional anti-inﬂammatory effects [9]. Much work
remains to be done to elucidate the mechanisms of DLPC activity
and to conﬁrm that these effects do not clear steatosis at the988 Journal of Hepatology 201expense of increased oxidative stress. It remains unclear how
DLPC enters the cell and, given the high concentrations of DLPC
required to produce an effect, it may be that DLPC mediates its
effects indirectly though a signaling cascade or by serving as a
metabolic precursor for the true LRH-1 ligand [15].
These new data are certainly encouraging and we await with
interest the results of the preliminary clinical trials that the
authors have initiated however, a word of caution. Like other
nuclear receptors, LRH-1 exhibits a wide spectrum of activity.
This includes inﬂuencing cellular replication and immunomodu-
lation [9]. LRH-1 has been shown to bind and activate hepatitis B
virus enhancer II and so increase viral replication within hepato-
cytes but perhaps of greatest concern, if LRH-1 agonists were to
be used as long-term therapy in NAFLD, are its potentially pro-
tumorigenic effects. LRH-1 activity regulates intestinal cell-cycle
control and estradiol synthesis and has been shown to promote
intestinal and breast tumor formation in murine models [9]. In
humans, the LRH-1 locus has also been genetically associated
with exocrine pancreatic neoplasia [9].
In conclusion, the work by Lee et al. provides new insights into
the role of nuclear receptors in sensing variations in intracellular
metabolite concentrations and the subsequent adaptive responses
they can illicit through modulation of downstream gene expres-
sion. The effects of DLPC signaling via LRH-1 in murine models
appear to have important therapeutic implications for NAFLD,
however, there remains uncertainty about the exact mechanisms
through which the effect is exerted and, for the moment at least,
there is reason to be cautious regarding the long-term implica-
tions of heightened LRH-1 activity.Conﬂict of interest
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